To summarize recent advances in CAR signaling biology and explore strategies for precise control of signal strength and quality in CAR T cell therapy.
Approach:
Enhancing CAR signaling: Examine strategies for improving CAR signaling through the addition of costimulatory domains.
Fine-tuning signaling: Explore emerging approaches that balance potency with durability in CAR designs.
Key Findings:
CAR signaling requirements are temporally dynamic, necessitating different signaling properties for initiation, amplification, and maintenance.
First-generation CARs showed limited efficacy due to insufficient signaling; second-generation CARs improved outcomes by incorporating costimulatory domains.
Excessive or prolonged CAR signaling can lead to T cell exhaustion and loss of persistence.
Interpretation:
Rational CAR design must consider not only the signaling output but also the timing and intensity of the signals to optimize therapeutic efficacy.
Limitations:
Current CAR designs may not fully replicate the regulatory features of native TCR signaling.
Challenges remain in extending CAR T cell therapy efficacy to solid tumors.
Conclusion:
Advancements in CAR signaling biology and design strategies, along with AI applications, may lead to more effective and personalized CAR T cell therapies.
Experts across Baptist Health Herbert Wertheim Cancer Institute and Eugene M. & Christine E. Lynn Cancer Institute will present new radiation oncology research and clinical expertise at the 2026 Annual Meeting of the American Society for Radiation Oncology (ASTRO), September 26-30, 2026, in Boston.
